Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer

Kunihiro Sakai, Tsunehisa Kaku, Toshiharu Kamura, Naoko Kinukawa, Satoshi Amada, Toshiyuki Shigematsu, Toshio Hirakawa, Hiroaki Kobayashi, Kazuya Ariyoshi, Hitoo Nakano

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.

Original languageEnglish
Pages (from-to)360-366
Number of pages7
JournalGynecologic Oncology
Volume72
Issue number3
DOIs
Publication statusPublished - Jan 1 1999

Fingerprint

Ovarian Neoplasms
Disease-Free Survival
Neoplasms
Multivariate Analysis
Neoplasm Metastasis
Ovarian epithelial cancer

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Sakai, K., Kaku, T., Kamura, T., Kinukawa, N., Amada, S., Shigematsu, T., ... Nakano, H. (1999). Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. Gynecologic Oncology, 72(3), 360-366. https://doi.org/10.1006/gyno.1998.5266

Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. / Sakai, Kunihiro; Kaku, Tsunehisa; Kamura, Toshiharu; Kinukawa, Naoko; Amada, Satoshi; Shigematsu, Toshiyuki; Hirakawa, Toshio; Kobayashi, Hiroaki; Ariyoshi, Kazuya; Nakano, Hitoo.

In: Gynecologic Oncology, Vol. 72, No. 3, 01.01.1999, p. 360-366.

Research output: Contribution to journalArticle

Sakai, K, Kaku, T, Kamura, T, Kinukawa, N, Amada, S, Shigematsu, T, Hirakawa, T, Kobayashi, H, Ariyoshi, K & Nakano, H 1999, 'Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer', Gynecologic Oncology, vol. 72, no. 3, pp. 360-366. https://doi.org/10.1006/gyno.1998.5266
Sakai, Kunihiro ; Kaku, Tsunehisa ; Kamura, Toshiharu ; Kinukawa, Naoko ; Amada, Satoshi ; Shigematsu, Toshiyuki ; Hirakawa, Toshio ; Kobayashi, Hiroaki ; Ariyoshi, Kazuya ; Nakano, Hitoo. / Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer. In: Gynecologic Oncology. 1999 ; Vol. 72, No. 3. pp. 360-366.
@article{c8b8ce6e29c542e39a9c759413070e66,
title = "Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer",
abstract = "Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28{\%}), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28{\%}), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.",
author = "Kunihiro Sakai and Tsunehisa Kaku and Toshiharu Kamura and Naoko Kinukawa and Satoshi Amada and Toshiyuki Shigematsu and Toshio Hirakawa and Hiroaki Kobayashi and Kazuya Ariyoshi and Hitoo Nakano",
year = "1999",
month = "1",
day = "1",
doi = "10.1006/gyno.1998.5266",
language = "English",
volume = "72",
pages = "360--366",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer

AU - Sakai, Kunihiro

AU - Kaku, Tsunehisa

AU - Kamura, Toshiharu

AU - Kinukawa, Naoko

AU - Amada, Satoshi

AU - Shigematsu, Toshiyuki

AU - Hirakawa, Toshio

AU - Kobayashi, Hiroaki

AU - Ariyoshi, Kazuya

AU - Nakano, Hitoo

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.

AB - Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032980607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032980607&partnerID=8YFLogxK

U2 - 10.1006/gyno.1998.5266

DO - 10.1006/gyno.1998.5266

M3 - Article

C2 - 10053108

AN - SCOPUS:0032980607

VL - 72

SP - 360

EP - 366

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -